A Prospective, Multicenter, Single Arm, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)
Phase of Trial: Phase II
Latest Information Update: 30 Jan 2018
At a glance
- Drugs Glatiramer acetate (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Mapi Pharma
- 30 Jan 2018 According to a Mapi Pharma media release, patients are currently being recruited at the Tel Aviv Sourasky Medical Center (Ichilov), The Barzilai Medical Center and Assaf Harofeh Medical Center.
- 30 Jan 2018 According to a Mapi Pharma media release, first patient has been treated.
- 30 Jan 2018 Status changed from not yet recruiting to recruiting, according to a Mapi Pharma media release.